Genetic adjuvant therapy for pancreatic cancer and other solid tumours

Bagley, Kenneth Christopher
March 2008
Gut;Mar2008, Vol. 57 Issue 3, p289
Academic Journal
The author reflects on the significant role of genetic adjuvant therapy in treating pancreatic cancer and other associated tumors. He demonstrates the cancer malignancies are the primary factor of all deaths in the world. He cites that the tumors can be treated in various medical approaches including surgical resection, chemotherapy or radiation. He believes that genetic adjuvant is used as an effective immunotherapy for tumor treatments.


Related Articles

  • Exosome-based immunotherapy. Chaput, Nathalie; Taïeb, Julien; Schartz, Noël E. C.; André, Fabrice; Angevin, Eric; Zitvogel, Laurence // Cancer Immunology, Immunotherapy;Mar2004, Vol. 53 Issue 3, p234 

    Exosomes are small membrane vesicles originating from late endosomes and secreted by hematopoietic and epithelial cells in culture. Exosome proteic and lipid composition is unique and might shed some light into exosome biogenesis and function. Exosomes secreted from professional...

  • Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients. Gandhi, Anita K.; Shi, Tao; Li, Mingyu; Jungnelius, Ulf; Romano, Alfredo; Tabernero, Josep; Siena, Salvatore; Schafer, Peter H.; Chopra, Rajesh // PLoS ONE;Nov2013, Vol. 8 Issue 11, p1 

    : This study assessed the immunomodulatory effects in previously treated KRAS-mutant metastatic colorectal cancer patients participating in a phase II multicenter, open-label clinical trial receiving lenalidomide alone or lenalidomide plus cetuximab. The main findings show the T cell...

  • Zn- and Mg- Containing Tricalcium Phosphates-Based Adjuvants for Cancer Immunotherapy. Xiupeng Wang; Xia Li; Kazuo Onuma; Yu Sogo; Tadao Ohno; Atsuo Ito // Scientific Reports;7/19/2013, p1 

    No abstract available.

  • Cancer immunotherapy: Benefit and harm? Characiejus, Dainius // OncoImmunology;Mar/Apr2012, Vol. 1 Issue 2, p232 

    In this article, evidence is reviewed suggesting that the outcome of cancer immunotherapy depends on pre-treatment immune parameters of a patient. The results described in the article show that immunotherapy may prolong survival in certain subgroups of cancer patients, while in other subgroups a...

  • Challenges facing adjuvants for cancer immunotherapy. Mesa, Circe; Fernández, Luis E. // Immunology & Cell Biology;Dec2004, Vol. 82 Issue 6, p644 

    An adjuvant is defined as a product that increases or modulates the immune response against an antigen (Ag). Based on this general definition many authors have postulated that the ideal adjuvant should increase the potency of the immune response, while being non-toxic and safe. Although dozens...

  • B cells for cancer immunotherapy. Deng, Jiusheng; Galipeau, Jacques // OncoImmunology;Oct2014, Vol. 3 Issue 10, pN.PAG 

    We have engineered a novel fusion cytokine named GIFT4 derived from GM-CSF and IL-4, and displaying robust gain-of-function immunostimulatory effects on B cells. GIFT4-programmed B cells have a unique identity and potent capacity to elicit a tumoricidal - cell response, thus comprising a novel B...

  • Chitin, Chitosan, and Glycated Chitosan Regulate Immune Responses: The Novel Adjuvants for Cancer Vaccine. Xiaosong Li; Min Min; Nan Du; Ying Gu; Hode, Tomas; Naylor, Mark; Dianjun Chen; Nordquist, Robert E.; Chen, Wei R. // Clinical & Developmental Immunology;2013, p1 

    With the development of cancer immunotherapy, cancer vaccine has become a novel modality for cancer treatment, and the important role of adjuvant has been realized recently. Chitin, chitosan, and their derivatives have shown their advantages as adjuvants for cancer vaccine. In this paper, the...

  • Antigenics's Oncophage approved for use in Russia.  // PharmaWatch: Cancer;May2008, Vol. 7 Issue 5, p12 

    The article reports on the approval of the Antigenics Inc.'s Oncophage in Russia for the treatment of non-metastatic, intermediate-risk renal cell carcinoma (RCC) patients. The Russian Ministry of Public Health has approved the vaccine for cancer treatment despite the lack of approval of...

  • NSCLC -- immunogenic after all? Kallen, Karl-Josef; Gnad-Vogt, Ulrike // Journal of Thoracic Disease;Jun2011, Vol. 3 Issue 2, p79 

    The article reports on the potential of immunotherapies in treating non-small cell lung cancer (NSCLC). The issue was addressed by a research team led by Hauke Winter, where they conducted randomized phase III tests involving active immunotherapies using oral talactoferrin, which activates...


Read the Article


Sign out of this library

Other Topics